

CURRICULUM VITAE

INFORMAZIONI PERSONALI

Cognome e Nome	CAPOBIANCO MARCO ALFONSO NARDUCCIO
Indirizzo istituzionale	AO S. CROCE E CARLE, VIA M. COPPINO 26 - CUNEO
Telefono istituzionale	0171641335
E-mail istituzionale	capobianco.m@ospedale.cuneo.it
Amministrazione	AZIENDA OSPEDALIERA S.CROCE E CARLE CUNEO
Qualifica	DIRIGENTE MEDICO
Incarico Aziendale	DIRETTORE STRUTTURA COMPLESSA DI NEUROLOGIA

FORMAZIONE ED ESPERIENZA LAVORATIVA

TITOLI DI STUDIO

		Master di II livello in Management per la direzione di struttura complessa, conseguito presso Università eCampus di Novedrate (CO) il 29/09/2016
		Specializzazione nella disciplina di NEUROLOGIA conseguita in data 10/12/2002 presso UNIVERSITA' DEGLI STUDI DI TORINO con votazione 60/60
		Laurea in MEDICINA E CHIRURGIA conseguita in data 23/07/1997 presso UNIVERSITA' DEGLI STUDI DI TORINO con votazione 110/110 lode e Tesi valutata Degna di Pubblicazione

ESPERIENZA LAVORATIVA

	dal 03.07.2007 al 19.06.2022 Dirigente Medico di Neurologia a tempo indeterminato, presso AOU San Luigi Gonzaga di Orbassano (SSN), con i seguenti incarichi dirigenziali: dal 03.07.2007 al 14.06.2012 Incarico di base di fascia "D"; dal 15.06.2012 al 31.01.2013 Incarico di base di fascia "D"; dal 01.02.2013 al 31.01.2016 Incarico di medie competenze tecnico-professionali di fascia "C2" dal titolo "Attività di Day Hospital e Day Service"; dal 01.02.2016 al 28.03.2017 Incarico di medie competenze tecnico-professionali di fascia "C2" dal titolo "Attività di Day Hospital e Day Service"; dal 29.03.2017 al 31.01.2018 Incarico di alta competenza tecnico-professionale di fascia "C1" dal titolo "Responsabile di Day Hospital e Day Service" dal 01.02.2018 al 14.01.2020 Conferimento incarico Professionale dal titolo "Gestione Clinica del Centro di riferimento Regionale per la Sclerosi Multipla (CRESM) e gestione delle altre malattie autoimmuni" di fascia "C1S"; dal 15.01.2020 al 14.01.2023 Conferimento incarico di alta Specializzazione di fascia "C" dal titolo "Gestione Clinica e organizzativa del CRESM e delle malattie autoimmuni del sistema nervoso centrale" dal 01.04.2021 al 19.06.2022 conferimento incarico di Direttore Facente Funzioni della SCDO Neurologia e Centro di Riferimento Regionale Sclerosi Multipla
	dal 01.12.2004 al 07.01.2006 Dirigente Medico di Neurologia a tempo determinato presso AOU San Luigi Gonzaga di Orbassano (SSN)
	dal 20.10.2004 al 29.11.2004 Incarico per 21 ore per Specialista Ambulatoriale di Neurologia presso ASL TO8 Distretto di Chieri (SSN)

ISTRUZIONE E FORMAZIONE

		Master di II livello Management per la direzione di struttura complessa sede Università e-Campus Periodo formativo AA 2015/2016, esame finale di laurea sostenuto il 29 settembre 2016
		Competenze di management per medici neurologi sede SDA Bocconi di Milano Periodo formativo: dal 1/3/2012 al 14/9/2012 - Durata 45 ore, esame finale con acquisizione di 50 crediti ECM
		Corso di sicurezza sul lavoro per dirigenti, E-LEARNING

	(così come definito dall' art.2, comma 1, lettera d) del D.Lgs.81/08, in riferimento all' art. 37, comma 7 D.Lgs.81/08 ed in relazione agli obblighi previsti dall' art. 18 ed in riferimento alla CSR del 21/12/2011 Rep.221) Erogato da: A.I.F.E.S.- ASSOCIAZIONE ITALIANA FORMATORI ED ESPERTI IN SICUREZZA Periodo formativo: da 02/07/2021 a 25/07/2021 - Durata: 16 ore con verifica dell'apprendimento
	Idoneità tecnica per espletamento dell'incarico di "addetto antincendio" corso per attività a rischio incendio elevato Comando Provinciale dei Vigili del Fuoco di Torino, 2/11/2017
	Partecipazione come moderatore e/o relatore a oltre 130 corsi/convegni in ambito neurologico

CAPACITÀ E COMPETENZE PERSONALI			
MADRELINGUA	ITALIANO		
ALTRE LINGUA			
	LINGUA	Livello parlato	Livello scritto
	INGLESE	BUONO	BUONO
ABILITAZIONI E ISCRIZIONI	Abilitazione Professionale e Iscrizione all'Ordine dei Medici e Chirurghi della Provincia di Torino dal 01/04/1998 N° TO18334		

PUBBLICAZIONI	PUBBLICAZIONI PEER-REVIEWED (H-INDEX WEB OF SCIENCE E SCOPUS 29)
	1. CEREPROSPINAL FLUID FINDINGS IN COVID-19: A MULTICENTER STUDY OF 150 LUMBAR PUNCTURES IN 127 PATIENTS. JARIUS S, PACHE F, KÖRTVELYESSY P, JELČIĆ I, STETTNER M, FRANCIOTTA D, KELLER E, NEUMANN B, RINGELSTEIN M, SENEL M, REGENER A, KALANTZIS R, WILLMS JF, BERTHELE A, BUSCH M, CAPOBIANCO M, EISELE A, REICHEN I, DERSCH R, RAUER S, SANDNER K, AYZENBERG I, GROSS CC, HEGEN H, KHALIL M, KLEITER I, LENHARDT T, HAAS J, AKTAS O, ANGSTWURM K, KLEINSCHNITZ C, LEWERENZ J, TUMANI H, PAUL F, STANGEL M, RUPRECHT K, WILDEMANN B; ; IN COOPERATION WITH THE GERMAN SOCIETY FOR CEREPROSPINAL FLUID DIAGNOSTICS AND CLINICAL NEUROCHEMISTRY. J NEUROINFLAMMATION. 2022 JAN 20;19(1):19. DOI: 10.1186/s12974-021-02339-0. 2. RISK OF GETTING COVID-19 IN PEOPLE WITH MULTIPLE SCLEROSIS: A CASE-CONTROL STUDY. IAFFALDANO P, LUCISANO G, MANNI A, PAOLICELLI D, PATTI F, CAPOBIANCO M, BRESCIA MORRA V, SOLA P, PESCI I, LUS G, DE LUCA G, LUGARESI A, CAVALLA P, MONTEPIETRA S, MANISCALCO GT, GRANELLA F, RAGONESE P, VIANELLO M, BRAMBILLA L, TOTARO R, TOSCANO S, MALUCCHI S, PETRACCA M, MOIOLA L, FERRARO D, LEPORE V, MOSCONI P, PONZIO M, TEDESCHI G, COMI G, BATTAGLIA MA, FILIPPI M, AMATO MP, TROJANO M; ITALIAN MS REGISTER. NEUROL NEUROIMMUNOL NEUROINFLAMM. 2022 JAN 19;9(2):E1141. DOI: 10.1212/NXI.0000000000001141. PRINT 2022 MAR. 3. COVID-19 SEVERITY IN MULTIPLE SCLEROSIS: PUTTING DATA INTO CONTEXT. SORMANI MP, SCHIAVETTI I, CARMISCIANO L, CORDIOLI C, FILIPPI M, RADAELLI M, IMMOVILLI P, CAPOBIANCO M, DE ROSSI N, BRICHETTO G, COCCO E, SCANDELLARI C, CAVALLA P, PESCI I, ZITO A, CONFALONIERI P, MARFIA GA, PERINI P, INGLESE M, TROJANO M, BRESCIA MORRA V, TEDESCHI G, COMI G, BATTAGLIA MA, PATTI F, SALVETTI M; MUSC-19 STUDY GROUP. NEUROL NEUROIMMUNOL NEUROINFLAMM. 2021 NOV 9;9(1):E1105. DOI: 10.1212/NXI.0000000000001105. PRINT 2022 JAN. PMID: 34753829 FREE PMC ARTICLE 4. THE EFFECT OF AIR POLLUTION ON COVID-19 SEVERITY IN A SAMPLE OF PATIENTS WITH MULTIPLE SCLEROSIS. BERGAMASCHI R, PONZANO M, SCHIAVETTI I, CARMISCIANO L, CORDIOLI C, FILIPPI M, RADAELLI M, IMMOVILLI P, CAPOBIANCO M, DE ROSSI N, BRICHETTO G, COCCO E, SCANDELLARI C, CAVALLA P, PESCI I, ZITO A, CONFALONIERI P, MARFIA GA, PERINI P, INGLESE M, TROJANO M, BRESCIA MORRA V, PISONI E, TEDESCHI G, COMI G, BATTAGLIA MA, PATTI F, SALVETTI M, SORMANI MP; MUSC-19 STUDY GROUP. EUR J NEUROL. 2021 NOV 4. DOI: 10.1111/ENE.15167. ONLINE AHEAD OF PRINT. PMID: 34735749 5. MULTIPLE SCLEROSIS EPIDEMIOLOGICAL TRENDS IN ITALY HIGHLIGHT THE ENVIRONMENTAL RISK FACTORS. PUTHENPARAMPIL M, PERINI P, BERGAMASCHI R, CAPOBIANCO M, FILIPPI M, GALLO P. J NEUROL. 2021 SEP 27. DOI: 10.1007/s00415-021-10782-5. ONLINE AHEAD OF PRINT. PMID: 34580756 REVIEW. 6. A REAL-WORLD STUDY OF ALEMTUZUMAB IN A COHORT OF ITALIAN PATIENTS. RUSSO CV, SACCÀ F, FRAU J, ANNOVAZZI P, SIGNORIELLO E, BONAVITA S, GRASSO R, CLERICO M, CORDIOLI C, LARONI A, CAPOBIANCO M, TORRI CLERICI V, SARTORI A, CAVALLA P, MANISCALCO GT, LA GIOIA S, CALERI F, GIUGNO A, IODICE R, CAROTENUTO A, COCCO E, FENU G, ZAFFARONI M, BARONCINI D, LUS G, GALLO A, DE MERCANTI SF, LAPUCCI C, DI FRANCESCANTONIO V, BRAMBILLA L, SORMANI MP, SIGNORI A. EUR J NEUROL. 2021 SEP 24. DOI: 10.1111/ENE.15121. ONLINE AHEAD OF PRINT. PMID: 34558755 7. SUCCESSFUL PREGNANCY AND DISEASE OUTCOMES IN A NMOSD PATIENT TREATED WITH TOCILIZUMAB. MARCO CAPOBIANCO, LUCA MAROZIO, SIMONA MALUCCHI, MARIA MALENTACCHI, MARIANNA LO RE, ALESSANDRA COSCIA, ANTONIO BERTOLOTTO. NEUROIMMUNOLOGY REPORTS. 8 SEPTEMBER 2021 VOLUME 1 (COVER DATE: DECEMBER 2021) ARTICLE 100014 8. MYELIN-OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE. MARIGNIER R, HACHEM Y, COBO-CALVO A, PRÖBSTEL AK, AKTAS O, ALEXOPOULOS H, AMATO MP, ASGARI N, BANWELL B, BENNETT J, BRILOT F, CAPOBIANCO M, CHITNIS T, CICCARELLI O, DEIVA K, DE SÈZE J, FUJIHARA K, JACOB A, KIM HJ, KLEITER I, LASSMANN H, LEITE MI, LININGTON C, MEINL E, PALACE J, PAUL F, PETZOLD A, PITTOCK S, REINDL M, SATO DK, SELMAJ K, SIVA A, STANKOFF B, TINTORE M, TRABOULSEE A, WATERS P, WAUBANT E, WEINSHENKER B, DERFUSS T, VUKUSIC S, HEMMER B. LANCET NEUROL. 2021 SEP;20(9):762-772. DOI: 10.1016/S1474-4422(21)00218-0. 9. SARS-CoV-2 SEROLOGY AFTER COVID-19 IN MULTIPLE SCLEROSIS: AN INTERNATIONAL COHORT STUDY. SORMANI MP, SCHIAVETTI I, LANDI D, CARMISCIANO L, DE ROSSI N, CORDIOLI C, MOIOLA L, RADAELLI M, IMMOVILLI P, CAPOBIANCO M, BRESCIA MORRA V, TROJANO M, TEDESCHI G, COMI G,

BATTAGLIA MA, PATTI F, FRAGOSO YD, SEN S, SIVA A, FURLAN R, SALVETTI M; MUSC-19 STUDY GROUP. MULT SCLER. 2021 JUL 30;13524585211035318. DOI: 10.1177/13524585211035318. ONLINE AHEAD OF PRINT. PMID: 34328824

10. RISK OF MULTIPLE SCLEROSIS RELAPSES WHEN SWITCHING FROM FINGOLIMOD TO CELL-DEPLETING AGENTS: THE ROLE OF WASHOUT DURATION. FERRARO D, IAFFALDANO P, GUERRA T, INGLESE M, CAPOBIANCO M, BRESCIA MORRA V, ZAFFARONI M, MIRABELLA M, LUS G, PATTI F, CAVALLA P, CELLERINO M, MALUCCHI S, PISANO E, VITETTA F, PAOLICELLI D, SOLA P, TROJANO M; ITALIAN MS REGISTER. J NEUROL. 2021 JUL 22. DOI: 10.1007/s00415-021-10708-1. ONLINE AHEAD OF PRINT. PMID: 34292396

11. DMTs AND COVID-19 SEVERITY IN MS: A POOLED ANALYSIS FROM ITALY AND FRANCE. SORMANI MP, SALVETTI M, LABAUGE P, SCHIAVETTI I, ZEPHIR H, CARMISCIANO L, BENSA C, DE ROSSI N, PELLETIER J, CORDIOLI C, VUKUSIC S, MOIOLA L, KERSCHEN P, RADAELLI M, THÉAUDIN M, IMMOVILLI P, CASEZ O, CAPOBIANCO M, CIRON J, TROJANO M, STANKOFF B, CRÉANGE A, TEDESCHI G, CLAVELOU P, COMI G, THOUVENOT E, BATTAGLIA MA, MOREAU T, PATTI F, DE SÈZE J, LOUAPRE C; MUSC-19; COVISEP STUDY GROUPS. ANN CLIN TRANSL NEUROL. 2021 AUG;8(8):1738-1744. DOI: 10.1002/acn3.51408. EPUB 2021 JUL 7. PMID: 34240579 FREE PMC ARTICLE.

12. FINGOLIMOD AS FIRST-LINE TREATMENT IN PEDIATRIC-ONSET MULTIPLE SCLEROSIS: A CASE REPORT. CAPOBIANCO M, BERLOLOTTO A, MALUCCHI S. NEUROL SCI. 2021 MAY;42(SUPPL 1):25-28. DOI: 10.1007/s10072-020-05027-8. EPUB 2021 MAR 12. PMID: 33712907

13. REAL WORLD EXPERIENCE WITH TERIFLUNOMIDE IN MULTIPLE SCLEROSIS: THE TER-ITALY STUDY. BUCELLO S, ANNOVAZZI P, RAGONESE P, ALTIERI M, BARCELLA V, BERGAMASCHI R, BIANCHI A, BORRIELLO G, BUSCARINU MC, CALLARI G, CAPOBIANCO M, CAPONE F, CAVALLA P, CAVARRETTA R, CORTESE A, DE LUCA G, DI FILIPPO M, DATTOLA V, FANTOZZI R, FERRARO E, FILIPPI MM, GASPERINI C, GRIMALDI LME, LANDI D, RE ML, MALLUCCI G, MANGANOTTI P, MARFIA GA, MIRABELLA M, PERINI P, PISA M, REALMUTO S, RUSSO M, TOMASSINI V, TORRI-CLERICI VLA, ZAFFARONI M, ZULIANI C, ZYWICKI S, FILIPPI M, PROSPERINI L. J NEUROL. 2021 FEB 22. DOI: 10.1007/s00415-021-10455-3. ONLINE AHEAD OF PRINT. PMID: 33616742

14. DISEASE-MODIFYING THERAPIES AND CORONAVIRUS DISEASE 2019 SEVERITY IN MULTIPLE SCLEROSIS. SORMANI MP, DE ROSSI N, SCHIAVETTI I, CARMISCIANO L, CORDIOLI C, MOIOLA L, RADAELLI M, IMMOVILLI P, CAPOBIANCO M, TROJANO M, ZARATIN P, TEDESCHI G, COMI G, BATTAGLIA MA, PATTI F, SALVETTI M; MUSC-19 STUDY GROUP. ANN NEUROL. 2021 JAN 21. DOI: 10.1002/ANA.26028. ONLINE AHEAD OF PRINT. PMID: 33480077

15. LONG-TERM CLINICAL OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS. BOFFA G, MASSACESI L, INGLESE M, MARIOTTINI A, CAPOBIANCO M, LUCIA M, AMATO MP, COTTONE S, GUALANDI F, DE GOBBI M, GRECO R, SCIMÈ R, FRAU J, ZIMATORE GB, BERLOLOTTO A, COMI G, UCCELLI A, SIGNORI A, ANGELUCCI E, INNOCENTI C, CICERI F, REPICE AM, SORMANI MP, SACCARDI R, MANCARDI G; ITALIAN BMT-MS STUDY GROUP. NEUROLOGY. 2021 JAN 20;10.1212/WNL.0000000000011461. DOI: 10.1212/WNL.0000000000011461. ONLINE AHEAD OF PRINT. PMID: 33472915

16. BENIGN SARS-CoV-2 INFECTION IN MOG-ANTIBODIES ASSOCIATED DISORDER DURING TOCILIZUMAB TREATMENT. MASUCCIO FG, LO RE M, BERLOLOTTO A, CAPOBIANCO M, SOLARO C. MULT SCLER RELAT DISORD. 2020 NOV;46:102592. DOI: 10.1016/J.MSARD.2020.102592. EPUB 2020 OCT 21. PMID: 33296987 FREE PMC ARTICLE.

17. E.U. PAEDIATRIC MOG CONSORTIUM CONSENSUS: PART 3 - BIOMARKERS OF PAEDIATRIC MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISORDERS. ARMANGUE T, CAPOBIANCO M, DE CHALUS A, LAETITIA G, DEIVA K; E.U. PAEDIATRIC MOG CONSORTIUM. EUR J PAEDIATR NEUROL. 2020 NOV;29:22-31. DOI: 10.1016/J.EJPN.2020.11.001. EPUB 2020 NOV 7. PMID: 33191096 REVIEW.

18. E.U. PAEDIATRIC MOG CONSORTIUM CONSENSUS: PART 4 - OUTCOME OF PAEDIATRIC MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISORDERS. BRUIJSTENS AL, BREU M, WENDEL EM, WASSMER E, LIM M, NEUTEBOOM RF, WICKSTRÖM R; E.U. PAEDIATRIC MOG CONSORTIUM. EUR J PAEDIATR NEUROL. 2020 NOV;29:32-40. DOI: 10.1016/J.EJPN.2020.10.007. EPUB 2020 NOV 4. PMID: 33183945 FREE ARTICLE. REVIEW. M. CAPOBIANCO IS LISTED IN THE EU PAEDIATRIC MOG CONSORTIUM.

19. E.U. PAEDIATRIC MOG CONSORTIUM CONSENSUS: PART 5 - TREATMENT OF PAEDIATRIC MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISORDERS. BRUIJSTENS AL, WENDEL EM, LECHNER C, BARTELS F, FINKE C, BREU M, FLET-BERLIAC L, DE CHALUS A, ADAMSBAUM C, CAPOBIANCO M, LAETITIA G, HACOEN Y, HEMINGWAY C, WASSMER E, LIM M, BAUMANN M, WICKSTRÖM R, ARMANGUE T, ROSTASY K, DEIVA K, NEUTEBOOM RF. EUR J PAEDIATR NEUROL. 2020 Nov;29:41-53. DOI: 10.1016/J.EJPN.2020.10.005. EPUB 2020 Nov 4. PMID: 33176999 FREE ARTICLE. REVIEW.
20. E.U. PAEDIATRIC MOG CONSORTIUM CONSENSUS: PART 1 - CLASSIFICATION OF CLINICAL PHENOTYPES OF PAEDIATRIC MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISORDERS. BRUIJSTENS AL, LECHNER C, FLET-BERLIAC L, DEIVA K, NEUTEBOOM RF, HEMINGWAY C, WASSMER E; E.U. PAEDIATRIC MOG CONSORTIUM. EUR J PAEDIATR NEUROL. 2020 Nov;29:2-13. DOI: 10.1016/J.EJPN.2020.10.006. EPUB 2020 Nov 4. PMID: 33162302 FREE ARTICLE. REVIEW. M. CAPOBIANCO IS LISTED IN THE EU PAEDIATRIC MOG CONSORTIUM
21. E.U. PAEDIATRIC MOG CONSORTIUM CONSENSUS: PART 2 - NEUROIMAGING FEATURES OF PAEDIATRIC MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISORDERS. BAUMANN M, BARTELS F, FINKE C, ADAMSBAUM C, HACOEN Y, ROSTÁSY K; E.U. PAEDIATRIC MOG CONSORTIUM. EUR J PAEDIATR NEUROL. 2020 Nov;29:14-21. DOI: 10.1016/J.EJPN.2020.10.002. EPUB 2020 Nov 4. PMID: 33158737 REVIEW. M. CAPOBIANCO IS LISTED IN THE EU PAEDIATRIC MOG CONSORTIUM
22. DETECTION OF DISABILITY WORSENING IN RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS: A REAL-WORLD ROVING EXPANDED DISABILITY STATUS SCALE REFERENCE ANALYSIS FROM THE ITALIAN MULTIPLE SCLEROSIS REGISTER. LEPORE V, BOSETTI C, SANTUCCI C, IAFFALDANO P, TROJANO M, MOSCONI P; ITALIAN MULTIPLE SCLEROSIS REGISTER CENTERS GROUP, THE SCIENTIFIC COMMITTEE OF ITALIAN SM REGISTER. EUR J NEUROL. 2021 FEB;28(2):567-578. DOI: 10.1111/ENE.14589. EPUB 2020 NOV 6. PMID: 33058344 M. CAPOBIANCO IS LISTED IN THE SCIENTIFIC COMMITTEE OF ITALIAN MS REGISTER
23. VACCINATIONS IN PATIENTS WITH MULTIPLE SCLEROSIS: A DELPHI CONSENSUS STATEMENT. RIVA A, BARCELLA V, BENATTI SV, CAPOBIANCO M, CAPRA R, CINQUE P, COMI G, FASOLO MM, FRANZETTI F, GALLI M, GEREVINI S, MERONI L, ORIGONI M, PROSPERINI L, PUOTI M, SCARPAZZA C, TORTORELLA C, ZAFFARONI M, MOIOLA L. MULT SCLER. 2021 MAR;27(3):347-359. DOI: 10.1177/1352458520952310. EPUB 2020 SEP 17. PMID: 32940128
24. THE RISK OF INFECTION IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH DISEASE-MODIFYING THERAPIES: A DELPHI CONSENSUS STATEMENT. MOIOLA L, BARCELLA V, BENATTI S, CAPOBIANCO M, CAPRA R, CINQUE P, COMI G, FASOLO MM, FRANZETTI F, GALLI M, GEREVINI S, MERONI L, ORIGONI M, PROSPERINI L, PUOTI M, SCARPAZZA C, TORTORELLA C, ZAFFARONI M, RIVA A. MULT SCLER. 2021 MAR;27(3):331-346. DOI: 10.1177/1352458520952311. EPUB 2020 SEP 17. PMID: 32940121
25. TREATMENT AND OUTCOME OF AQUAPORIN-4 ANTIBODY-POSITIVE NMOSD: A MULTINATIONAL PEDIATRIC STUDY. PAOLILLO RB, HACOEN Y, YAZBECK E, ARMANGUE T, BRUIJSTENS A, LECHNER C, APOSTOLOS-PEREIRA SL, MARTYNYENKO Y, BREU M, DE MEDEIROS RIMKUS C, WASSMER E, BAUMANN M, PAPETTI L, CAPOBIANCO M, KORNEK B, ROSTÁSY K, DA PAZ JA, CICCARELLI O, LIM M, SAIZ A, NEUTEBOOM R, MARIGNIER R, HEMINGWAY C, SATO DK, DEIVA K. NEUROL NEUROIMMUNOL NEUROINFLAMM. 2020 JUL 30;7(5):E837. DOI: 10.1212/NXI.0000000000000837. PRINT 2020 SEP. PMID: 32732259 FREE PMC ARTICLE.
26. TREATMENT OF MOG-IGG-ASSOCIATED DISORDER WITH RITUXIMAB: AN INTERNATIONAL STUDY OF 121 PATIENTS. WHITTAM DH, COBO-CALVO A, LOPEZ-CHIRIBOGA AS, PARDO S, GORNALL M, CICONI S, BRANDT A, BEREK K, BERGER T, JELCIC I, GOMBOLAY G, OLIVEIRA LM, CALLEGARO D, KANEKO K, MISU T, CAPOBIANCO M, GIBBONS E, KARTHIKEAYAN V, BROCHET B, AUDOIN B, MATHEY G, LAPLAUD D, THOUVENOT E, COHEN M, TOURBAH A, MAILLART E, CIRON J, DESCHAMPS R, BIOTTI D, ROSTASY K, NEUTEBOOM R, HEMINGWAY C, FORSYTH R, MATIELLO M, WEBB S, HUNT D, MURRAY K, HACOEN Y, LIM M, LEITE MI, PALACE J, SOLOMON T, LUTTEROTTI A, FUJIHARA K, NAKASHIMA I, BENNETT JL, PANDIT L, CHITNIS T, WEINSHENKER BG, WILDEMANN B, SATO DK, KIM SH, HUDA S, KIM HJ, REINDL M, LEVY M, JARIUS S, TENEMBAUM S, PAUL F, PITTOCK S, MARIGNIER R, JACOB A. MULT SCLER RELAT DISORD. 2020 SEP;44:102251. DOI: 10.1016/J.MSARD.2020.102251. EPUB 2020 JUN 2. PMID: 32629363 FREE PMC ARTICLE.
27. TREATMENT OF MOG ANTIBODY ASSOCIATED DISORDERS: RESULTS OF AN INTERNATIONAL SURVEY. WHITTAM DH, KARTHIKEAYAN V, GIBBONS E, KNEEN R, CHANDRATRE S, CICCARELLI O, HACOEN Y,

- DE SEZE J, DEIVA K, HINTZEN RQ, WILDEMANN B, JARIUS S, KLEITER I, ROSTASY K, HUPPKE P, HEMMER B, PAUL F, AKTAS O, PRÖBSTEL AK, ARRAMBIDE G, TINTORE M, AMATO MP, NOSADINI M, MANCARDI MM, CAPOBIANCO M, ILLES Z, SIVA A, ALTINTAS A, AKMAN-DEMIR G, PANDIT L, APIWATTANKUL M, HOR JY, VISWANATHAN S, QIU W, KIM HJ, NAKASHIMA I, FUJIHARA K, RAMANATHAN S, DALE RC, BOGGILD M, BROADLEY S, LANA-PEIXOTO MA, SATO DK, TENENBAUM S, CABRE P, WINGERCHUK DM, WEINSHENKER BG, GREENBERG B, MATIELLO M, KLAWITER EC, BENNETT JL, WALLACH AI, KISTER I, BANWELL BL, TRABOULSEE A, POHL D, PALACE J, LEITE MI, LEVY M, MARIGNIER R, SOLOMON T, LIM M, HUDA S, JACOB A. J NEUROL. 2020 DEC;267(12):3565-3577. DOI: 10.1007/s00415-020-10026-Y. EPUB 2020 JUL 4. PMID: 32623595
28. COMBINATION TREATMENT WITH SECUKINUMAB AND DIMETHYL FUMARATE IN A PATIENT WITH PSORIASIS AND RECENT DIAGNOSIS OF MULTIPLE SCLEROSIS. DI TULLIO F, ODORICI G, LASAGNI C, CAPOBIANCO M, CONTI A, MANDEL VD. DERMATOL THER. 2020 NOV;33(6):E13943. DOI: 10.1111/DTH.13943. EPUB 2020 JUL 14. PMID: 32614114
29. AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT): STANDARD OF CARE FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS. BERTOLOTTO A, MARTIRE S, MIRABILE L, CAPOBIANCO M, DE GOBBI M, CILLONI D. NEUROL THER. 2020 DEC;9(2):197-203. DOI: 10.1007/s40120-020-00200-9. EPUB 2020 JUN 16. PMID: 32548740 FREE PMC ARTICLE.
30. CONCOMITANT BRAIN ARTERIAL AND VENOUS THROMBOSIS IN A COVID-19 PATIENT. MALENTACCHI M, GNED D, ANGELINO V, DEMICHELIS S, PERBONI A, VELTRI A, BERTOLOTTO A, CAPOBIANCO M. EUR J NEUROL. 2020 SEP;27(9):E38-E39. DOI: 10.1111/ENE.14380. EPUB 2020 JUN 30. PMID: 32503080 FREE PMC ARTICLE.
31. EFFECTIVENESS OF FINGOLIMOD IN REAL-WORLD RELAPSING-REMITTING MULTIPLE SCLEROSIS ITALIAN PATIENTS: THE GENIUS STUDY. COMI G, POZZILLI C, MORRA VB, BERTOLOTTO A, SANGALLI F, PROSPERINI L, CAROTENUTO A, IAFFALDANO P, CAPOBIANCO M, COLOMBO D, NICA M, RIZZOLI S, TROJANO M. NEUROL SCI. 2020 OCT;41(10):2843-2851. DOI: 10.1007/s10072-020-04380-Y. EPUB 2020 APR 21. PMID: 32318950 FREE PMC ARTICLE.
32. EFFICACY OF DIFFERENT RITUXIMAB THERAPEUTIC STRATEGIES IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDERS. NOVI G, BOVIS F, CAPOBIANCO M, FRAU J, MATALUNI G, CURTI E, ZULIANI L, CAVALLA P, BRAMBILLA L, ANNOVAZZI P, REPICE AM, LANZILLO R, ESPOSITO S, BENEDETTI L, MAIETTA I, SICA F, BUTTARI F, MALUCCHI S, FENU G, LANDI D, BOSA C, REALMUTO S, MALENTACCHI M, GRANELLA F, SIGNORI A, BONAVITA S, UCCELLI A, SORMANI MP; IMUST GROUP. MULT SCLER RELAT DISORD. 2019 NOV;36:101430. DOI: 10.1016/J.MSARD.2019.101430. EPUB 2019 OCT 4. PMID: 31610404
33. TREATMENT OF MULTIPLE SCLEROSIS WITH RITUXIMAB: A MULTICENTRIC ITALIAN-SWISS EXPERIENCE. ZECCA C, BOVIS F, NOVI G, CAPOBIANCO M, LANZILLO R, FRAU J, REPICE AM, HAKIKI B, REALMUTO S, BONAVITA S, CURTI E, BRAMBILLA L, MATALUNI G, CAVALLA P, DI SAPIO A, SIGNORIELLO E, BARONE S, MANISCALCO GT, MAIETTA I, MARAFFI I, BOFFA G, MALUCCHI S, NOZZOLILLO A, COGHE G, MECCHI C, SALEMI G, GALLO A, SACCO R, CELLERINO M, MALENTACCHI M, DE ANGELIS M, LOREFICE L, MAGNANI E, PRESTIPINO E, SPERLI F, BRESCIA MORRA V, FENU G, BARILARO A, ABBADESSA G, SIGNORI A, GRANELLA F, AMATO MP, UCCELLI A, GOBBI C, SORMANI MP. MULT SCLER. 2020 OCT;26(12):1519-1531. DOI: 10.1177/1352458519872889. EPUB 2019 OCT 1. PMID: 31573386
34. RETROSPECTIVELY ACQUIRED COHORT STUDY TO EVALUATE THE LONG-TERM IMPACT OF TWO DIFFERENT TREATMENT STRATEGIES ON DISABILITY OUTCOMES IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS (RE.LO.DI.MS): DATA FROM THE ITALIAN MS REGISTER. PAOLICELLI D, LUCISANO G, MANNI A, AVOLIO C, BONAVITA S, BRESCIA MORRA V, CAPOBIANCO M, COCCO E, CONTE A, DE LUCA G, DE ROBERTIS F, GASPERINI C, GATTO M, GAZZOLA P, LUS G, IAFFALDANO A, IAFFALDANO P, MAIMONE D, MALLUCCI G, MANISCALCO GT, MARFIA GA, PATTI F, PESCI I, POZZILLI C, ROVARIS M, SALEMI G, SALVETTI M, SPITALERI D, TOTARO R, ZAFFARONI M, COMI G, AMATO MP, TROJANO M; ITALIAN MS REGISTER. J NEUROL. 2019 DEC;266(12):3098-3107. DOI: 10.1007/s00415-019-09531-6. EPUB 2019 SEP 18. PMID: 31535270
35. SCARPAZZA C, SIGNORI A, PROSPERINI L, SORMANI MP, COSOTTINI M, CAPRA R, GEREVINI S; ITALIAN PML GROUP. EARLY DIAGNOSIS OF PROGRESSIVE MULTIFOCAL LEUCOENCEPHALOPATHY: LONGITUDINAL LESION EVOLUTION. J NEUROL NEUROSURG PSYCHIATRY. 2018 NOV 2. PII: JNNP-2018-319208. DOI: 10.1136/JNNP-2018-319208. [EPUB AHEAD OF PRINT] PUBMED PMID: 30389778. CAPOBIANCO M IS LISTED IN THE ITALIAN PML GROUP. M. CAPOBIANCO IS LISTED IN THE ITALIAN PML

	GROUP 36. PROSPERINI L, ANNOVAZZI P, BOFFA L, BUSCARINU MC, GALLO A, MATTA M, MOIOLA L, MUSU L, PERINI P, AVOLIO C, BARCELLA V, BIANCO A, FARINA D, FERRARO E, PONTECORVO S, GRANELLA F, GRIMALDI LME, LARONI A, LUS G, PATTI F, PUCCI E, PASCA M, SARCHIELLI P; ITALIAN ALEMTUZUMAB STUDY GROUP. NO EVIDENCE OF DISEASE ACTIVITY (NEDA-3) AND DISABILITY IMPROVEMENT AFTER ALEMTUZUMAB TREATMENT FOR MULTIPLE SCLEROSIS: A 36-MONTH REAL-WORLD STUDY. J NEUROL. 2018 DEC;265(12):2851-2860. DOI: 10.1007/s00415-018-9070-x. EPUB 2018 SEP 26. PUBMED PMID: 30259178. CAPOBIANCO M IS LISTED IN THE ITALIAN ALEMTUZUMAB STUDY GROUP. 37. MARCINNÒ A, MARNETTO F, VALENTINO P, MARTIRE S, BALBO A, DRAGO A, LETO M, CAPOBIANCO M, PANZICA G, BERTOLOTTO A. RITUXIMAB-INDUCED HYPOGAMMAGLOBULINEMIA IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDERS. NEUROL NEUROIMMUNOL NEUROINFLAMM. 2018 SEP 13;5(6):E498. DOI: 10.1212/NXI.0000000000000498. ECOLLECTION 2018 NOV. PUBMED PMID: 30258855; PUBMED CENTRAL PMCID: PMC6148550. 38. BARONCINI D, ZAFFARONI M, MOIOLA L, LOREFICE L, FENU G, IAFFALDANO P, SIMONE M, FANELLI F, PATTI F, D'AMICO E, CAPOBIANCO M, BERTOLOTTO A, GALLO P, MARGONI M, MIANTE S, MILANI N, AMATO MP, RIGHINI I, BELLANTONIO P, SCANDELLARI C, COSTANTINO G, SCARPINI E, BERGAMASCHI R, MALLUCCI G, COMI G, GHEZZI A; IMED REGISTRY AND GRUPPO DI STUDIO SM-SOCIETÀ ITALIANA DI NEUROLOGIA. LONG-TERM FOLLOW-UP OF PEDIATRIC MS PATIENTS STARTING TREATMENT WITH INJECTABLE FIRST-LINE AGENTS: A MULTICENTRE, ITALIAN, RETROSPECTIVE, OBSERVATIONAL STUDY. MULT SCLER. 2018 JAN 1;1352458518754364. DOI: 10.1177/1352458518754364. [EPUB AHEAD OF PRINT] PUBMED PMID: 29363396. 39. SCARPAZZA C, PROSPERINI L, MANCINELLI CR, DE ROSSI N, LUGARESI A, CAPOBIANCO M, MOIOLA L, NALDI P, IMBERTI L, GEREVINI S, CAPRA R. IS MARAVIROC USEFUL IN MULTIPLE SCLEROSIS PATIENTS WITH NATALIZUMAB-RELATED PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY? J NEUROL SCI. 2017 JUL 15;378:233-237. DOI: 10.1016/J.JNS.2017.05.018. EPUB 2017 MAY 12. PMID: 28566170 40. MAROLA S, FERRARESE A, GIBIN E, CAPOBIANCO M, BERTOLOTTO A, ENRICO S, SOLEJ M, MARTINO V, DESTEFANO I, NANO M. ANAL SPHINCTER DYSFUNCTION IN MULTIPLE SCLEROSIS: AN OBSERVATION MANOMETRIC STUDY. OPEN MED (WARS). 2016 NOV 25;11(1):509-517. DOI: 10.1515/MED-2016-0088. ECOLLECTION 2016. PUBMED PMID: 28352843; PUBMED CENTRAL PMCID: PMC5329875. 41. LANDI D, DE ROSSI N, ZAGAGLIA S, SCARPAZZA C, PROSPERINI L, ALBANESE M, BUTTARI F, MORI F, MARFIA GA, SORMANI MP, CAPRA R, CENTONZE D; ITALIAN PML STUDY GROUP (CAPOBIANCO M IS LISTED IN THE ITALIAN PML STUDY GROUP). NO EVIDENCE OF BENEFICIAL EFFECTS OF PLASMAPHERESIS IN NATALIZUMAB-ASSOCIATED PML. NEUROLOGY. 2017 MAR 21;88(12):1144-1152. DOI: 10.1212/WNL.00000000000003740. EPUB 2017 FEB 22. PUBMED PMID: 28228569. 42. VALENTINO P, MARNETTO F, GRANIERI L, CAPOBIANCO M, BERTOLOTTO A. AQUAPORIN-4 ANTIBODY TITRATION IN NMO PATIENTS TREATED WITH RITUXIMAB: A RETROSPECTIVE STUDY. NEUROL NEUROIMMUNOL NEUROINFLAMM. 2016 DEC 15;4(2):E317. DOI: 10.1212/NXI.0000000000000317. ECOLLECTION 2017 MAR. PUBMED PMID: 28054001; PUBMED CENTRAL PMCID: PMC5182057. 43. MALUCCHI S, CAPOBIANCO M, LO RE M, MALENTACCHI M, DI SAPIO A, MATTA M, SPERLI F, BERTOLOTTO A. HIGH-RISK PML PATIENTS SWITCHING FROM NATALIZUMAB TO ALEMTUZUMAB: AN OBSERVATIONAL STUDY. NEUROL THER. 2016 DEC 3. [EPUB AHEAD OF PRINT] PUBMED PMID: 27915429. 44. JARIUS S, RUPRECHT K, KLEITER I, BORISOW N, ASGARI N, PITAROKOILI K, PACHE F, STICH O, BEUME LA, HÜMMERT MW, RINGELSTEIN M, TREBST C, WINKELMANN A, SCHWARZ A, BUTTMANN M, ZIMMERMANN H, KUCHLING J, FRANCIOTTA D, CAPOBIANCO M, SIEBERT E, LUKAS C, KORPORAL-KUHNKE M, HAAS J, FECHNER K, BRANDT AU, SCHANDA K, AKTAS O, PAUL F, REINDL M, WILDEMANN B; IN COOPERATION WITH THE NEUROMYELITIS OPTICA STUDY GROUP (NEMOS).. MOG-IGG IN NMO AND RELATED DISORDERS: A MULTICENTER STUDY OF 50 PATIENTS. PART 2: EPIDEMIOLOGY, CLINICAL PRESENTATION, RADIOLOGICAL AND LABORATORY FEATURES, TREATMENT RESPONSES, AND LONG-TERM OUTCOME. J NEUROINFLAMMATION. 2016 SEP 27;13(1):280. PUBMED PMID: 27793206; PUBMED CENTRAL PMCID: PMC5086042. 45. JARIUS S, RUPRECHT K, KLEITER I, BORISOW N, ASGARI N, PITAROKOILI K, PACHE F, STICH O, BEUME LA, HÜMMERT MW, TREBST C, RINGELSTEIN M, AKTAS O, WINKELMANN A, BUTTMANN M,
--	---

SCHWARZ A, ZIMMERMANN H, BRANDT AU, FRANCIOTTA D, CAPOBIANCO M, KUCHLING J, HAAS J, KORPORAL-KUHNKE M, LILLEVANG ST, FECHNER K, SCHANDA K, PAUL F, WILDEMANN B, REINDL M; IN COOPERATION WITH THE NEUROMYELITIS OPTICA STUDY GROUP (NEMOS).. MOG-IGG IN NMO AND RELATED DISORDERS: A MULTICENTER STUDY OF 50 PATIENTS. PART 1: FREQUENCY, SYNDROME SPECIFICITY, INFLUENCE OF DISEASE ACTIVITY, LONG-TERM COURSE, ASSOCIATION WITH AQP4-IGG, AND ORIGIN. J NEUROINFLAMMATION. 2016 SEP 26;13(1):279. PubMed PMID: 27788675; PubMed Central PMCID: PMC5084340.

46. RITUXIMAB IN THE TREATMENT OF NEUROMYELITIS OPTICA: A MULTICENTRE ITALIAN OBSERVATIONAL STUDY. ANNOVAZZI P, CAPOBIANCO M, MOIOLA L, PATTI F, FRAU J, UCCELLI A, CENTONZE D, PERINI P, TORTORELLA C, PROSPERINI L, LUS G, FUIANI A, FALCINI M, MARTINELLI V, COMI G, GHEZZI A. J NEUROL. 2016 SEP;263(9):1727-35. DOI: 10.1007/s00415-016-8188-Y. EPUB 2016 JUN 10.

47. NORMATIVE VALUES FOR INTERTRIAL VARIABILITY OF MOTOR RESPONSES TO NERVE ROOT AND TRANSCRANIAL STIMULATION: A CONDITION FOR FOLLOW-UP STUDIES IN INDIVIDUAL SUBJECTS. TRONI W, MELILLO F, BERTOLOTTO A, MALUCCHI S, CAPOBIANCO M, SPERLI F, DI SAPIO A. PLoS ONE. 2016 MAY 16;11(5):e0155268. DOI: 10.1371/JOURNAL.PONE.0155268. ECollection 2016.

48. SUBCUTANEOUS INTERFERON B-1A IN PEDIATRIC PATIENTS WITH MULTIPLE SCLEROSIS: REGIONAL DIFFERENCES IN CLINICAL FEATURES, DISEASE MANAGEMENT, AND TREATMENT OUTCOMES IN AN INTERNATIONAL RETROSPECTIVE STUDY. KRUPP LB, POHL D, GHEZZI A, BOYKO A, TENENBAUM S, CHEN L, AYCARDI E, BANWELL B; REPLAY STUDY GROUP (CAPOBIANCO M IS LISTED IN THE REPLAY STUDY GROUP). J NEUROL SCI. 2016 APR 15;363:33-8.

49. THE CASE | THE YOUNG PHILOSOPHER WITH MULTIPLE SCLEROSIS AND PROTEINURIA. PICCOLI GB, CAPOBIANCO M, VIGOTTI FN, NARETTO C, NARIOZ C, BROCHERIOU I, ROCCATELLO D. KIDNEY INT. 2016 APR;89(4):961-3.

50. PECULIAR CYTOLOGICAL CEREBROSPINAL FLUID PATTERN IN A CASE OF ENCEPHALOMYELITIS DURING ANTI-TUMOR NECROSIS FACTOR- α THERAPY. MOTUZOVA Y, DI SAPIO A, CAPOBIANCO M, SALA A, MARNETTO F, MALUCCHI S, BERTOLOTTO A. NEUROL THER. 2015 JUN;4(1):53-60. DOI: 10.1007/s40120-015-0027-z. EPUB 2015 MAR 6.

51. NATALIZUMAB DISCONTINUATION AND TREATMENT STRATEGIES IN PATIENTS WITH MULTIPLE SCLEROSIS (MS): A RETROSPECTIVE STUDY FROM TWO ITALIAN MS CENTERS. LO RE M, CAPOBIANCO M, RAGONESE P, REALMUTO S, MALUCCHI S, BERTCHIALLA P, SALEMI G, BERTOLOTTO A. NEUROL THER. 2015 DEC;4(2):147-57. DOI: 10.1007/s40120-015-0038-9. EPUB 2015 DEC 8.

52. VITAMIN D BINDING PROTEIN ISOFORMS AND APOLIPOPROTEIN E IN CEREBROSPINAL FLUID AS PROGNOSTIC BIOMARKERS OF MULTIPLE SCLEROSIS. PERGA S, GIULIANO ALBO A, LIS K, MINARI N, FALVO S, MARNETTO F, CALDANO M, REVIGLIONE R, BERTCHIALLA P, CAPOBIANCO M, MALENTACCHI M, CORPILLO D, BERTOLOTTO A. PLoS ONE. 2015 JUN 5;10(6):e0129291.

53. THE USE OF THE 25 SPOTTE NEEDLE MARKEDLY REDUCES POST-DURAL PUNCTURE HEADACHE IN ROUTINE NEUROLOGICAL PRACTICE. BERTOLOTTO A, MALENTACCHI M, CAPOBIANCO M, DI SAPIO A, MALUCCHI S, MOTUZOVA Y, PULIZZI A, BERTCHIALLA P, SPERLI F. CEPHALALGIA. 2016 FEB;36(2):131-8.

54. NATALIZUMAB DISCONTINUATION IN PATIENTS WITH MULTIPLE SCLEROSIS: PROFILING RISK AND BENEFITS AT THERAPEUTIC CROSSROADS. PROSPERINI L, ANNOVAZZI P, CAPOBIANCO M, CAPRA R, BUTTARI F, GASPERINI C, GALGANI S, SOLARO C, CENTONZE D, BERTOLOTTO A, POZZILLI C, GHEZZI A. MULT SCLER. 2015 NOV;21(13):1713-22. DOI: 10.1177/1352458515570768. EPUB 2015 FEB 19.

55. BIOLOGICAL MONITORING OF IFN- β THERAPY IN MULTIPLE SCLEROSIS. BERTOLOTTO A, GRANIERI L, MARNETTO F, VALENTINO P, SALA A, CAPOBIANCO M, MALUCCHI S, DI SAPIO A, MALENTACCHI M, MATTÀ M, CALDANO M. CYTOKINE GROWTH FACTOR REV. 2015 APR;26(2):241-8.

56. CD19 mRNA QUANTIFICATION IMPROVES RITUXIMAB TREATMENT-TO-TARGET APPROACH: A PROOF OF CONCEPT STUDY. MARNETTO F, GRANIERI L, VALENTINO P, CAPOBIANCO M, PAUTASSO M, BERTOLOTTO A. J NEUROIMMUNOL. 2014 SEP 20. pii: S0165-5728(14)00885-6. DOI: 10.1016/J.JNEUROIM.2014.09.008. [EPUB AHEAD OF PRINT]

57. NO IMPACT OF CURRENT THERAPEUTIC STRATEGIES ON DISEASE REACTIVATION AFTER NATALIZUMAB

	DISCONTINUATION: A COMPARATIVE ANALYSIS OF DIFFERENT APPROACHES DURING THE FIRST YEAR OF NATALIZUMAB DISCONTINUATION. CAPOBIANCO M, DI SAPIO A, MALENTACCHI M, MALUCCHI S, MATTA M, SPERLI F, BERTOLOTTO A. EUR J NEUROL. 2014 JUL 3. doi: 10.1111/ENE.12487. [EPUB AHEAD OF PRINT] 58. INTERFERON BETA-RELATED NEPHROPATHY AND INTERSTITIAL LUNG DISEASE: A NEW ASSOCIATION AND A LONG-TERM WARNING. CAPOBIANCO M, PICCOLI G, NEVE VIGOTTI F, SCAPOLI P, DEAGOSTINI MC, ALBERA C, ROCCATELLO D, BERTOLOTTO A. MULT SCLER. 2014 JAN 20. [EPUB AHEAD OF PRINT] PMID: 24446386 59. GUIDELINES ON THE CLINICAL USE FOR THE DETECTION OF NEUTRALIZING ANTIBODIES (NABS) TO IFN BETA IN MULTIPLE SCLEROSIS THERAPY: REPORT FROM THE ITALIAN MULTIPLE SCLEROSIS STUDY GROUP. BERTOLOTTO A, CAPOBIANCO M, AMATO MP, CAPELLO E, CAPRA R, CENTONZE D, DI IOIA M, GALLO A, GRIMALDI L, IMBERTI L, LUGARESI A, MANCINELLI C, MARROSU MG, MOIOLA L, MONTANARI E, ROMANO S, MUSU L, PAOLICELLI D, PATTI F, POZZILLI C, ROSSI S, SALVETTI M, TEDESCHI G, TOLA MR, TROIANO M, ZAFFARONI M, MALUCCHI S. NEUROL SCI. 2013 DEC 29. [EPUB AHEAD OF PRINT] PMID: 24374787 60. SUBCUTANEOUS INTERFERON BETA-1A IN PEDIATRIC MULTIPLE SCLEROSIS: A RETROSPECTIVE STUDY. TENEMBAUM SN, BANWELL B, POHL D, KRUPP LB, BOYKO A, MEINEL M, LEHR L, ROCAK S, CANTOGNO EV, MORAGA MS, GHEZZI A; REPLAY STUDY GROUP. J CHILD NEUROL. 2013 JUL;28(7):849-56. (CAPOBIANCO M IS LISTED IN THE REPLAY STUDY GROUP) 61. EVALUATION OF A MULTIPARAMETRIC IMMUNOFLUORESCENCE ASSAY FOR STANDARDIZATION OF NEUROMYELITIS OPTICA SEROLOGY. GRANIERI L, MARNETTO F, VALENTINO P, FRAU J, PATANELLA AK, NYTROVA P, SOLA P, CAPOBIANCO M, JARIUS S, BERTOLOTTO A. PLoS ONE. 2012;7(6):E38896. 62. AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION WITH AN INTERMEDIATE INTENSITY CONDITIONING REGIMEN IN MULTIPLE SCLEROSIS: THE ITALIAN MULTI-CENTRE EXPERIENCE. MANCARDI G, SORMANI M, DI GIOIA M, VUOLO L, GUALANDI F, AMATO M, CAPELLO E, CURRÒ D, UCCELLI A, BERTOLOTTO A, GASPERINI C, LUGARESI A, MERELLI E, MEUCCI G, MOTTI L, TOLA M, SCARPINI E, REPICE A, MASSACESI L, SACCARDI R; THE ITALIAN BMT STUDY GROUP. MULT SCLER. 2012 JUN;18(6):835-842. EPUB 2011 NOV 29. (CAPOBIANCO M IS LISTED IN THE ITALIAN BMT STUDY GROUP) 63. NATALIZUMAB IN AGGRESSIVE MULTIPLE SCLEROSIS AFTER HAEMATOPOIETIC STEM CELL TRANSPLANTATION. CAPOBIANCO M, MOTUZOVA Y, FRAU J, COCCO E, MAMUSA E, MARROSU MG, BERTOLOTTO A. NEUROL SCI. 2011 NOV 64. ACUTE MYELOID LEUKEMIA IN ITALIAN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH MITOXANTRONE. MARTINELLI V, COCCO E, CAPRA R, SALEMI G, GALLO P, CAPOBIANCO M, PESCI I, GHEZZI A, POZZILLI C, LUGARESI A, BELLANTONIO P, AMATO MP, GRIMALDI LM, TROJANO M, MANCARDI GL, BERGAMASCHI R, GASPERINI C, RODEGHER M, STRAFFI L, PONZIO M, COMI G; ITALIAN MITOXANTRONE GROUP. NEUROLOGY. 2011 NOV 22;77(21):1887-95. EPUB 2011 NOV 9. 65. LOSS OF BRAKING SIGNALS DURING INFLAMMATION: A FACTOR AFFECTING THE DEVELOPMENT AND DISEASE COURSE OF MULTIPLE SCLEROSIS. GILLI F, NAVONE ND, PERGA S, MARNETTO F, CALDANO M, CAPOBIANCO M, PULIZZI A, MALUCCHI S, BERTOLOTTO A. ARCH NEUROL. 2011 MAR 14. [EPUB AHEAD OF PRINT] 66. ONE-YEAR EVALUATION OF FACTORS AFFECTING THE BIOLOGICAL ACTIVITY OF INTERFERON BETA IN MULTIPLE SCLEROSIS PATIENTS. MALUCCHI S, GILLI F, CALDANO M, SALA A, CAPOBIANCO M, DI SAPIO A, GRANIERI L, BERTOLOTTO A. J NEUROL. 2011 MAY;258(5):895-903. EPUB 2010 DEC 12. 67. PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN GOOD'S SYNDROME. CAPOBIANCO M, PULIZZI A, BERTOLOTTO A. INT J INFECT DIS. 2010 SEP;14 SUPPL 3:E367-8. EPUB 2010 JUN 18. 68. LEARNING FROM NATURE: PREGNANCY CHANGES THE EXPRESSION OF INFLAMMATION-RELATED GENES IN PATIENTS WITH MULTIPLE SCLEROSIS. GILLI F, LINDBERG RL, VALENTINO P, MARNETTO F, MALUCCHI S, SALA A, CAPOBIANCO M, DI SAPIO A, SPERLI F, KAPPOS L, CALOGERO RA, BERTOLOTTO A. PLoS ONE. 2010 JAN 29;5(1):E8962. 69. WESTERN BLOT ANALYSIS FOR THE DETECTION OF SERUM ANTIBODIES RECOGNIZING LINEAR
--	--

	AQUAPORIN-4 EPITOPES IN PATIENTS WITH NEUROMYELITIS OPTICA. MARNETTO F, HELLIAS B, GRANIERI L, FRAU J, PATANELLA AK, NYTROVA P, SALA A, CAPOBIANCO M, GILLI F, BERTOLOTTO A. J NEUROIMMUNOL. 2009 DEC 10;217(1-2):74-9. EPUB 2009 OCT 21. 70. LONG-TERM RESULTS OF IMMUNOMODULATORY TREATMENT IN CHILDREN AND ADOLESCENTS WITH MULTIPLE SCLEROSIS: THE ITALIAN EXPERIENCE. GHEZZI A, AMATO MP, ANNOVAZZI P, CAPOBIANCO M, GALLO P, LA MANTIA L, MARROSU MG, MARTINELLI V, MILANI N, MOIOLA L, PATTI F, POZZILLI C, TROJANO M, ZAFFARONI M, COMI G; ITEMS (IMMUNOMODULATORY TREATMENT OF EARLY-ONSET MS) GROUP. NEUROL SCI. 2009 JUN;30(3):193-9. EPUB 2009 APR 22. 71. EXPRESSION AND REGULATION OF IFNα/BETA RECEPTOR IN IFNβ-TREATED PATIENTS WITH MULTIPLE SCLEROSIS. GILLI F, VALENTINO P, CALDANO M, GRANIERI L, CAPOBIANCO M, MALUCCHI S, SALA A, MARNETTO F, BERTOLOTTO A. NEUROLOGY. 2008 DEC 9;71(24):1940-7. EPUB 2008 OCT 29. 72. GLATIRAMER ACETATE IS A TREATMENT OPTION IN NEUTRALISING ANTIBODIES TO INTERFERON-BETA-POSITIVE PATIENTS. CAPOBIANCO M, RIZZO A, MALUCCHI S, SPERLI F, DI SAPIO A, OGGERO A, ZAFFARONI M, GHEZZI A, BERTOLOTTO A. NEUROL SCI. 2008 SEP;29 SUPPL 2:S227-9. 73. ACUTE MYELOID LEUKEMIA INDUCED BY MITOXANTRONE TREATMENT FOR AGGRESSIVE MULTIPLE SCLEROSIS. CAPOBIANCO M, MALUCCHI S, ULISCIANI S, FAVA C, CAMBRIN GR, AVONTO L, SAGLIO G, BERTOLOTTO A. NEUROL SCI. 2008 JUN;29(3):185-7. EPUB 2008 JUL 9. 74. PREDICTIVE MARKERS FOR RESPONSE TO INTERFERON THERAPY IN PATIENTS WITH MULTIPLE SCLEROSIS. MALUCCHI S, GILLI F, CALDANO M, MARNETTO F, VALENTINO P, GRANIERI L, SALA A, CAPOBIANCO M, BERTOLOTTO A. NEUROLOGY. 2008 MAR 25;70(13 Pt 2):1119-27. EPUB 2008 FEB 13. 75. ANTI-INTERFERON-BETA NEUTRALISING ACTIVITY IS NOT ENTIRELY MEDIATED BY ANTIBODIES. GILLI F, MARNETTO F, CALDANO M, VALENTINO P, GRANIERI L, DI SAPIO A, CAPOBIANCO M, SALA A, MALUCCHI S, KAPPOS L, LINDBERG RL, BERTOLOTTO A. J NEUROIMMUNOL. 2007 DEC;192(1-2):198-205. EPUB 2007 OCT 22. 76. VARIABLE RESPONSES TO RITUXIMAB TREATMENT IN NEUROMYELITIS OPTICA (DEVIC'S DISEASE). CAPOBIANCO M, MALUCCHI S, DI SAPIO A, GILLI F, SALA A, BOTTERO R, MARNETTO F, DORIGUZZI BOZZO C, BERTOLOTTO A. NEUROL SCI. 2007 AUG;28(4):209-11. EPUB 2007 AUG 10. 77. TREATMENT OF EARLY-ONSET MULTIPLE SCLEROSIS WITH INTRAMUSCULAR INTERFERONβ-1A: LONG-TERM RESULTS. GHEZZI A, AMATO MP, CAPOBIANCO M, GALLO P, MARROSU MG, MARTINELLI V, MILANESE C, MOIOLA L, MILANI N, LA MANTIA L, PATTI F, POZZILLI C, TROJANO M, COMI G, ZAFFARONI M; IMMUNOMODULATORY TREATMENT OF EARLY-ONSET MS (ITEMS) GROUP. NEUROL SCI. 2007 JUN;28(3):127-32. EPUB 2007 JUN 30. 78. DEVELOPMENT AND VALIDATION OF A REAL TIME PCR-BASED BIOASSAY FOR QUANTIFICATION OF NEUTRALIZING ANTIBODIES AGAINST HUMAN INTERFERON-BETA. BERTOLOTTO A, SALA A, CALDANO M, CAPOBIANCO M, MALUCCHI S, MARNETTO F, GILLI F. J IMMUNOL METHODS. 2007 APR 10;321(1-2):19-31. EPUB 2007 FEB 20. 79. AUTOLOGOUS STEM CELL TRANSPLANTATION FOR PROGRESSIVE MULTIPLE SCLEROSIS: UPDATE OF THE EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION AUTOIMMUNE DISEASES WORKING PARTY DATABASE. SACCARDI R, KOZAK T, BOCELLI-TYNDALL C, FASSAS A, KAZIS A, HAVRDOVA E, CARRERAS E, SAIZ A, LÖWENBERG B, TE BOEKHORST PA, GUALANDIO F, OPENSHAW H, LONGO G, PAGLIAI F, MASSACESI L, DECONINK E, OUYANG J, NAGORE FJ, BESALDUCH J, LISUKOV IA, BONINI A, MERELLI E, SLAVINO S, GRATWOHL A, PASSWEG J, TYNDALL A, STECK AJ, ANDOLINA M, CAPOBIANCO M, MARTIN JL, LUGARESÍ A, MEUCCI G, SÁEZ RA, CLARK RE, FERNANDEZ MN, FOUILLARD L, HERSTENSTEIN B, KOZA V, COCCO E, BAURMANN H, MANCARDI GL; AUTOIMMUNE DISEASES WORKING PARTY OF EBMT. MULT SCLER. 2006 DEC;12(6):814-23. 80. HIGH-DOSE GLUCOCORTICOIDS INCREASE SERUM LEVELS OF SOLUBLE IL-6 RECEPTOR α AND ITS RATIO TO SOLUBLE GP130: AN ADDITIONAL MECHANISM FOR EARLY INCREASED BONE RESORPTION. DOVIO A, PERAZZOLO L, SABA L, TERMINE A, CAPOBIANCO M, BERTOLOTTO A, ANGELI A. EUR J ENDOCRINOL. 2006 MAY;154(5):745-51.
--	--

	81. BIOLOGICAL MARKERS OF INTERFERON-BETA THERAPY: COMPARISON AMONG INTERFERON-STIMULATED GENES MxA, TRAIL AND XAF-1. GILLI F, MARNETTO F, CALDANO M, SALA A, MALUCCHI S, CAPOBIANCO M, BERTOLOTTO A. MULT SCLER. 2006 FEB;12(1):47-57. 82. FATE OF MULTIPLE SCLEROSIS PATIENTS POSITIVE FOR NEUTRALISING ANTIBODIES TOWARDS INTERFERON BETA SHIFTED TO ALTERNATIVE TREATMENTS. MALUCCHI S, CAPOBIANCO M, GILLI F, MARNETTO F, CALDANO M, SALA A, BERTOLOTTO A. NEUROL SCI. 2005 DEC;26 SUPPL 4:S213-4. 83. DISEASE-MODIFYING DRUGS IN CHILDHOOD-JUVENILE MULTIPLE SCLEROSIS: RESULTS OF AN ITALIAN CO-OPERATIVE STUDY. GHEZZI A, AMATO MP, CAPOBIANCO M, GALLO P, MARROSU G, MARTINELLI V, MILANI N, MILANESE C, MOIOLA L, PATTI F, PILATO V, POZZILLI C, TROJANO M, ZAFFARONI M, COMI G; IMMUNOMODULATORY TREATMENT OF EARLY ONSET MS GROUP. MULT SCLER. 2005 AUG;11(4):420-4. 84. BIOLOGICAL RESPONSIVENESS TO FIRST INJECTIONS OF INTERFERON-BETA IN PATIENTS WITH MULTIPLE SCLEROSIS. GILLI F, MARNETTO F, CALDANO M, SALA A, MALUCCHI S, DI SAPIO A, CAPOBIANCO M, BERTOLOTTO A. J NEUROIMMUNOL. 2005 JAN;158(1-2):195-203. 85. BIOLOGICAL ACTIVITY OF INTERFERON BETAS IN PATIENTS WITH MULTIPLE SCLEROSIS IS AFFECTED BY TREATMENT REGIMEN AND NEUTRALISING ANTIBODIES. BERTOLOTTO A, SALA A, MALUCCHI S, MARNETTO F, CALDANO M, DI SAPIO A, CAPOBIANCO M, GILLI F. J NEUROL NEUROSURG PSYCHIATRY. 2004 SEP;75(9):1294-9. 86. NEUTRALIZING ANTIBODIES REDUCE THE EFFICACY OF BETA1FN DURING TREATMENT OF MULTIPLE SCLEROSIS. MALUCCHI S, SALA A, GILLI F, BOTTERO R, DI SAPIO A, CAPOBIANCO M, BERTOLOTTO A. NEUROLOGY. 2004 JUN 8;62(11):2031-7. 87. NEUTRALIZING ANTIBODIES AGAINST IFN-BETA IN MULTIPLE SCLEROSIS: ANTAGONIZATION OF IFN-BETA MEDIATED SUPPRESSION OF MMPs. GILLI F, BERTOLOTTO A, SALA A, HOFFMANN F, CAPOBIANCO M, MALUCCHI S, GLASS T, KAPPOS L, LINDBERG RL, LEPPERT D. BRAIN. 2004 FEB;127(Pt 2):259-68. EPUB 2003 NOV 7. 88. NEUROMYELITIS OPTICA: IMPORTANCE OF CEREBROSPINAL FLUID EXAMINATION DURING RELAPSE. MILANO E, DI SAPIO A, MALUCCHI S, CAPOBIANCO M, BOTTERO R, SALA A, GILLI F, BERTOLOTTO A. NEUROL SCI. 2003 OCT;24(3):130-3. 89. THE QUALITY OF NEUROLOGY RESIDENCY PROGRAMMES IN ITALY. CAPOBIANCO M, MANCUSO M, TRIGGIANI L, SCARAVILLI T, BONIFATI DM; ITALIAN TRAINEES ASSOCIATION. LANCET NEUROL. 2003 OCT;2(10):594; DISCUSSION 594. 90. PERSISTENT NEUTRALIZING ANTIBODIES ABOLISH THE INTERFERON BETA BIOAVAILABILITY IN MS PATIENTS. BERTOLOTTO A, GILLI F, SALA A, CAPOBIANCO M, MALUCCHI S, MILANO E, MELIS F, MARNETTO F, LINDBERG RL, BOTTERO R, DI SAPIO A, GIORDANA MT. NEUROLOGY. 2003 FEB 25;60(4):634-9. 91. DIFFERENTIAL EFFECTS OF THREE INTERFERON BETAS ON NEUTRALISING ANTIBODIES IN PATIENTS WITH MULTIPLE SCLEROSIS: A FOLLOW UP STUDY IN AN INDEPENDENT LABORATORY. BERTOLOTTO A, MALUCCHI S, SALA A, OREFICE G, CARRIERI PB, CAPOBIANCO M, MILANO E, MELIS F, GIORDANA MT. J NEUROL NEUROSURG PSYCHIATRY. 2002 AUG;73(2):148-53. 92. INTERFERON BETA NEUTRALIZING ANTIBODIES IN MULTIPLE SCLEROSIS: NEUTRALIZING ACTIVITY AND CROSS-REACTIVITY WITH THREE DIFFERENT PREPARATIONS. BERTOLOTTO A, MALUCCHI S, MILANO E, CASTELLO A, CAPOBIANCO M, MUTANI R. IMMUNOPHARMACOLOGY. 2000 JUL 20;48(2):95-100. 93. QUANTITATIVE PCR REVEALS INCREASED LEVELS OF TUMOR NECROSIS FACTOR-ALPHA MRNA IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF MULTIPLE SCLEROSIS PATIENTS DURING RELAPSES. BERTOLOTTO A, MALUCCHI S, CAPOBIANCO M, MANZARDO E, GUASTAMACCHIA G, MILANO E, AUDANO L, MUTANI R. J INTERFERON CYTOKINE RES. 1999 JUN;19(6):575-81. 94. TRANSFORMING GROWTH FACTOR BETA1 (TGFbeta1) MRNA LEVEL CORRELATES WITH MAGNETIC RESONANCE IMAGING DISEASE ACTIVITY IN MULTIPLE SCLEROSIS PATIENTS. BERTOLOTTO A, CAPOBIANCO M, MALUCCHI S, MANZARDO E, AUDANO L, BERGUI M, BRADAC GB, MUTANI R. NEUROSCI LETT. 1999 MAR 19;263(1):21-4.
--	--

Data di ultimo aggiornamento: 20/07/2022

Si autorizza al trattamento dei dati personali secondo quanto indicato nel D.Lgs 196/03 e s.m.i e GDPR 2016/679 .
In ottemperanza al DPR 445/00 e s.m.i il sottoscritto dichiara, sotto la propria ed esclusiva responsabilità, che quanto riportato nel presente curriculum corrisponde al vero.